Cornerstone Investment Partners LLC boosted its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 0.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 35,481 shares of the company’s stock after buying an additional 52 shares during the period. Cornerstone Investment Partners LLC’s holdings in Teva Pharmaceutical Industries were worth $1,632,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the company. Webster Bank N. A. raised its position in Teva Pharmaceutical Industries by 3.6% in the second quarter. Webster Bank N. A. now owns 8,638 shares of the company’s stock valued at $434,000 after buying an additional 300 shares during the last quarter. TT International raised its position in Teva Pharmaceutical Industries by 8.7% in the second quarter. TT International now owns 1,375,183 shares of the company’s stock valued at $69,075,000 after buying an additional 109,780 shares during the last quarter. Benjamin F. Edwards & Company Inc. raised its position in Teva Pharmaceutical Industries by 14.4% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 4,742 shares of the company’s stock valued at $238,000 after buying an additional 597 shares during the last quarter. Macnealy Hoover Investment Management Inc. raised its position in Teva Pharmaceutical Industries by 1.9% in the second quarter. Macnealy Hoover Investment Management Inc. now owns 13,180 shares of the company’s stock valued at $662,000 after buying an additional 250 shares during the last quarter. Finally, Trust Co raised its position in Teva Pharmaceutical Industries by 0.3% in the first quarter. Trust Co now owns 13,980 shares of the company’s stock valued at $748,000 after buying an additional 40 shares during the last quarter. 60.53% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) traded down 0.16% during trading on Monday, reaching $38.15. The company had a trading volume of 4,883,086 shares. Teva Pharmaceutical Industries Ltd. has a 12 month low of $37.12 and a 12 month high of $66.55. The stock has a market capitalization of $38.72 billion, a PE ratio of 22.19 and a beta of 0.73. The stock’s 50-day moving average price is $41.37 and its 200-day moving average price is $49.12.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Tuesday, November 15th. The company reported $1.31 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.29 by $0.02. The company earned $5.56 billion during the quarter, compared to analyst estimates of $5.71 billion. Teva Pharmaceutical Industries had a return on equity of 16.75% and a net margin of 8.81%. The business’s revenue was up 15.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.35 earnings per share. Equities analysts forecast that Teva Pharmaceutical Industries Ltd. will post $5.14 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 20th. Stockholders of record on Monday, December 5th will be issued a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 3.56%. The ex-dividend date of this dividend is Thursday, December 1st. Teva Pharmaceutical Industries’s dividend payout ratio (DPR) is presently 50.58%.

ILLEGAL ACTIVITY WARNING: “Teva Pharmaceutical Industries Ltd. (TEVA) Position Boosted by Cornerstone Investment Partners LLC” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this article can be read at https://www.thecerbatgem.com/2016/11/28/teva-pharmaceutical-industries-ltd-teva-position-boosted-by-cornerstone-investment-partners-llc.html.

Several equities analysts recently issued reports on the company. Mizuho reissued a “buy” rating and set a $70.00 target price (down previously from $75.00) on shares of Teva Pharmaceutical Industries in a research note on Friday, August 5th. Leerink Swann restated an “outperform” rating and set a $66.00 price target on shares of Teva Pharmaceutical Industries in a report on Tuesday, August 16th. Guggenheim restated a “buy” rating and set a $80.00 price target on shares of Teva Pharmaceutical Industries in a report on Monday, August 15th. Piper Jaffray Cos. restated a “neutral” rating and set a $57.00 price target (up previously from $55.00) on shares of Teva Pharmaceutical Industries in a report on Monday, August 8th. Finally, Oppenheimer Holdings Inc. downgraded Teva Pharmaceutical Industries from an “outperform” rating to a “market perform” rating and set a $70.29 price target on the stock. in a report on Friday, August 5th. Twelve research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Teva Pharmaceutical Industries currently has an average rating of “Buy” and a consensus target price of $59.80.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

5 Day Chart for NYSE:TEVA

Receive News & Stock Ratings for Teva Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd. and related stocks with our FREE daily email newsletter.